TG Therapeutics, Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday, StockTargetPrices.com reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 300.00% from the stock’s current price.

Several other brokerages have also commented on TGTX. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. BidaskClub upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $26.78.

Shares of TG Therapeutics (NASDAQ TGTX) opened at $8.25 on Tuesday. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. analysts forecast that TG Therapeutics will post -1.79 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “TG Therapeutics, Inc. (TGTX) Given “Buy” Rating at HC Wainwright” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/14/tg-therapeutics-inc-tgtx-given-buy-rating-at-hc-wainwright.html.

Institutional investors have recently modified their holdings of the stock. Legal & General Group Plc increased its stake in shares of TG Therapeutics by 4.1% in the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in TG Therapeutics during the 2nd quarter valued at about $156,000. Bank of America Corp DE grew its position in TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,395 shares during the last quarter. HighTower Advisors LLC purchased a new stake in TG Therapeutics during the 1st quarter valued at about $170,000. Finally, BB&T Securities LLC grew its position in TG Therapeutics by 63.0% during the 2nd quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 6,549 shares during the last quarter. Institutional investors own 49.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Stock Target Prices

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.